LASSBio-1632 是具有抗哮喘活性的先导化合物，可选择性抑制PDE4A和PDE4D同工酶，阻断肺组织中气道的高反应性和TNF-α 产生。LASSBio-1632 (7j) 具有良好的 BBB 渗透性。

LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion [1].

C18H20N2O6S

392.43

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years